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Background: Aegle marmelos (L.) Corr. (Rutaceae), commonly known as bael, is used to treat fevers, abdomen pain,
palpitation of the heart, urinary troubles, melancholia, anorexia, dyspepsia, diabetes and diarrhea in Indian traditional
systems of medicine. The object of the present study was to evaluate the antidiabetic, antihyperlipidemic and
antioxidant oxidative stress of umbelliferone β-D-galactopyranoside (UFG) from stem bark of Aegle marmelos Correa. in
STZ (streptozotocin) induced diabetic rat.
Methods: Diabetes was induced in rat by single intraperitoneal injection of STZ (60 mg/kg). The rat was divided into
the following groups; I – normal control, II – diabetic control, III – UFG (10 mg/kg), IV – UFG (20 mg/kg), V – UFG
(40 mg/kg), VI – Glibenclamide (10 mg/kg, p.o., once a daily dose). Diabetes was measured by change the level blood
glucose, plasma insulin and the oxidative stress were assessed in the liver by estimation of the level of antioxidant
markers i.e. superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and Malondialdehyde (MDA) and
antihyperlipidemic effect was measured by estimation of total cholesterol, triglycerides, LDL (low density lipoprotein)
cholesterol, HDL (high density lipoprotein) cholesterol, VLDL (very low density lipoprotein) cholesterol. However in a
study, the increased body weight was observed and utilization of glucose was in the oral glucose tolerance test.
Result: Daily oral administration of different dose of UFG for 28 days showed significantly (P < 0.001) decreased in
fasting blood glucose level and improve plasma insulin level as compared to the diabetic control group. Also it
significantly (P < 0.001) decreased the level of glycated hemoglobin, glucose-6-phosphatase, fructose-1-6-biphosphate
and increased the level of hexokinase. UFG treatment decreased liver MDA and increased the level of SOD, GPx and
CAT. UFG treatment of lipids it’s increased the level of cholesterol, triglycerides, VLDL, LDL cholesterol and decreased
the level of HDL cholesterol. Histologically, inflammatory cell in blood vessels, intercalated disc, fat degeneration and
focal necrosis observed in diabetic rat organ but was less obvious in UFG treated groups. The mechanism of action of
UFG may be due to the increased level of pancreatic insulin secretion and effect on the antioxidant marker.
Conclusion: UFG posses an antidiabetic, antioxidant and antihyperlipidemic effect on the STZ induced diabetic rat.
Hence it could be the better choice to cure the diabetes.
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Diabetes mellitus (DM) has very long historical ac-
counts; it first points up in the medical text of several
ancient cultures over 2000 year ago. According to the re-
ports that, 135 million adults affected from the diabetes
mellitus in year 1995 worldwide and the data will in-
crease to 300 million in the year 2025 [1,2]. Diabetes
mellitus is a very common health problem arise world-
wide rapidly, due changing the food habit, lifestyle and
largely consumption of fast food. Major reason is gener-
ation of free radical formation, free radical generation
caused by degeneration of carbohydrates, lipid and protein
metabolism by increased blood glucose level (hypergly-
caemia) resulting from the defects in insulin secretion, in-
sulin action or both. Elevated glucose production causes
oxidative stress and as a result there is increase in mito-
chondrial reactive oxygen species (ROS), non-enzymatic
glycation of proteins and glucose autoxidation [3]. In dia-
betes, increased oxidative stress is due to generation of
free radical and reduction of antioxidant defenses [4]. En-
dogenous antioxidant enzymes are responsible for the de-
toxification of injurious oxygen radicals. Evidences from
epidemiological and biological studies have established
that reactive oxygen species (ROS) are involved in a var-
iety of physiological and pathological processes [5]. Differ-
ent grades of synthetic drugs, herbal formulation available
in the market therefore they are investigated with renewed
interest all over the world [6,7]. A lot of classes of syn-
thetic drug are available in the market but quite a few
herbal drugs are being employed in the treatment of dia-
betes mellitus. Only metformin is the one example of a
drug which is obtained from the herb (Galega officinalis)
with a very long history of use for diabetes. Still re-
searching is going on to find out the more effective herbal
drug to cure the diabetes and reduced the free radical for-
mation with minimized side effect.
Aegle marmelos Correa. (Rutaceae) plant is found in
all over India and also called as IndianQuince, holy fruit
(According to Hindu mythology it is holy plant), Bengal
quince, Golden Apple (English), ilvam (Tamil) Bilva,
Sriphal, Shivadruma, Shivapala (Sanskrit) Bil (Gujarati),
Bel (Bangali) and Beal (Hindi) [7-9]. Different parts of
the plant (fruit, seed, leaves, root, bark and flowers) are
used in preparation of various herbal preparations. The
used of bael was having very long history. The most
commonly used part is the fruit; fruit juice was strained
and sweetened to make a drink similar to lemonade. In
Ayurveda fruit are used for heart, stomach, intestinal tonic,
chronic constipation and dysentery; some forms of indiges-
tion, typhoid, debility, fever, hemorrhoids, hypochondria,
melancholia and for heart palpitation. Various chemical
constituents like Alkaloids, coumarins and steroids have
been isolated and characterized from different part of the
tree, such as leaves, fruit, wood, root and bark [10].The present research exertion was taken up to evalu-
ate the anti-diabetic activity of Umbelliferone β-D-
galactopyranoside isolated from the stem bark of Aegle
marmelos Correa. Since in the previous research [11] it
was established that Umbelliferone is a potent free rad-
ical scavenger and works as antioxidant. Till date no
study has been reported on the antioxidant activity of
Umbelliferone β-D-galactopyranoside and the major root
cause of diabetes mellitus is the development of free rad-
icals which destroys the β-cells of the pancreatic islets
[3], responsible for the secretion of insulin. Therefore,
we have taken up the isolated compound for the evalu-
ation against the diabetes, hyperlipidemia and oxidation.
Methods
General
Melting point was set up on a Veego, Model No. MPI is
melting point apparatus and are uncorrected. 1H NMR
spectra were recorded on Bruker Avance II 400 NMR
Spectrophotometer and 13C NMR spectra on BrukerAvance
II 100 NMR Spectrophotometer in DMSO using TMS as
internal standard. Mass spectra were obtained on the VG-
AUTOSPEC spectrometer. UV λmax (DMSO) were re-
corded on Shimadzu UV-1700 and FT-IR (in 2.0 cm-1,
flat, smooth, Abex) were taken on Perkin Elmer –
Spectrum RX-I spectrophotometer.
Material
The stem bark of Aegle marmelos Correa. collected from
the botanical garden, Department of Pharmaceutical
Sciences, Faculty of Health Sciences, Sam Higginbottom
Institute of Agriculture, Technology & Sciences – Deemed
University and authenticated by Dr. Imran Kajmi
(Pharmacognosist) and a specimen voucher (SIP/HD/054/
12) of the plant sample respectively have been deposited
in the herbarium of Siddhartha Institute of Pharmacy,
Dehradun, Uttrakhand, India.
Chemical
Silica gel (60–120 mesh) (Nicholas India Pvt. Ltd) and
glass column were used for column chromatography.
Streptozotocin (Sigma Chemical Co. USA), GOD/POD
kit, Cholesterol kit, Triglyceride kit, (Span, India), Gliben-
clamide (purity > 99%), Carboxyl methyl cellulose (SD
fine, India), chemicals and other solvents used for the
chromatography isolation and experimental protocol of
analytical grade and were purchased from respective
vendor, Allahabad, India.
Extraction and isolation
The shade dry stem bark of Aegle marmelos Correa
(2 kg) was extracted with methanol (5 L) at the 45°C for
72 h [12,13]. After extraction total filtrate was concen-
trated to dryness in rotatory vacuum evaporator at 40°C
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small amount of methanol and was absorbed on silica
gel (60–120 mesh). It is subjected to silica gel column
using as a C6H14/CHCl3/MeOH gradient system (1:0:0,
2:0:0, 4:0:0, 4:1:0, 1:1:0, 1:4:0, 1:6:0, 0:1:0, 0:48:0, 0:24:1,
0:48:2, 0:10:0, 0:10:1, 0:24:7, and 0:47:10; 3.0 L for each
gradient system), yielding 22 fractions collected fraction
spotted on pre coated silica gel TLC plate and the frac-
tion having the same Rf value pooled together in 7 frac-
tions. Fractions 2–4 (13.5 g) were combined separated on a
silica gel column (CHCl3/MeOH, 3:1), and rechroma-
tographed on a silica gel column (CHCl3/MeOH, 6:1 to 3:1),
yielding 7 subtractions. Compound 1 was separated first by
a normal phase silica gel column (CHCl3/MeOH, 3:1).
Animals
Swiss albino wistar rats (150–220 g) was used for the study.
The animals were housed under standard conditions of
temperature (25 ± 1°C), relative humidity (55 ± 10%), 12 hr/
12 hour light/dark cycles and animals were received stand-
ard pellet diet (Lipton rat feed, Ltd., Pune) with and water
ad libitum. The experimental protocol was approved by
the Institutional Animal Ethical Committee of Siddhartha
Institute of Pharmacy (1435/PO/a/11/CPCSEA).
Acute toxicity study
The toxicity study was conducted as per the guidelines
of CPCSEA, article no 420. A separate experiment per-
formed for determination of any toxic effect of the test
drug. For acute toxicity study, normal healthy wistar rats
were fasted overnight (16 hour) and randomly divided
into different groups and each groups contain rats (n = 10).
Wistar rat was treated with starting doses (0.05, 0.10, 0.50
and 0.100 g/kg body weight) of test compound and the
control group was treated with vehicle alone (CMC 2%;
1 ml/kg body weight). All the animal groups allowed for
food and water ad libitum and were observed over a
period of 2 h for changing in various autonomical
(defecation and urination), neurological (touch, reactivity,
spontaneous, pain response and gait) and behavior (alert-
ness, restlessness, irritability, and fearfulness) responses
and after 24 and 48 h for mortality [14,15]. If mortality
caused by the compound within this period of the time
was observed [16].
Assessment of UFG in oral glucose tolerance test
Assessment of oral glucose tolerance test, healthy rats
were divided into seven groups of six animals each [17].
Group I. Normal control rats received CMC.
Group II. Normal control rats received UFG
(40 mg/kg p.o.).
Group III. Glucose (2 gm/kg) received rats.
Group IV. Glucose treated diabetic rats received UFG
(10 mg/kg p.o.).Group V. Glucose treated diabetic rats received UFG
(20 mg/kg p.o.).
Group VI. Glucose treated diabetic rats received UFG
(40 mg/kg p.o.).
Group VII. Glucose treated diabetic rats received
glibenclamide (10 mg/kg p.o.).
All group animals received drug and vehicle orally. All
the animals were received glucose (2 g/kg) 30 min after
dosing. The blood sample was collected from puncture of
retro-orbital of an eye; their glucose tolerance was studied
up to 2 h at regular interval of 0, 30, 60, 120 min each.
Induction of diabetes
Wistar rats were injected diabetes by a single intra-
peritoneal injection of streptozotocin (60 mg/kg body
weight). Volume of STZ 1 ml/kg body weight prepared
by STZ dissolving in freshly prepared 0.01 M citrate buf-
fer (pH = 4. 5) [18]. After 3 days administration of STZ
(streptozotocin) blood glucose level of rats were esti-
mated. Rats with a blood glucose level of 220 mg/dL be-
yond considered as diabetic [19].
Experimental design
Wistar rats were divided into seven groups and six ani-
mals in each group [20].
Group I. Normal control rats received citrate buffer
(pH = 4.5) for 28 days (1 ml/kg p.o.).
Group II. Normal control rats received UFG
(40 mg/kg p.o.) and continued for 28 days.
Group III. STZ-diabetic rats received vehicle only.
Group IV. STZ treated diabetic rats received UFG
(10 mg/kg p.o.) and continued for 28 days.
Group V. STZ treated diabetic rats received UFG
(20 mg/kg p.o.) and continued for 28 days.
Group VI. STZ treated diabetic rats received UFG
(40 mg/kg p.o.) and continued for 28 days.
Group VII. STZ treated diabetic rats received gliben-
clamide (10 mg/kg p.o.) and continued for 28 days.
All groups animal received drug and vehicle orally,
once daily. Blood was collected on the regular interval
by retro-orbital puncture under mild an anesthesia and
measure blood glucose level and collected blood sample
was centrifuged and examined for plasma glucose ana-
lysis by a GOD - POD method using the Glucose Esti-
mation Kit (Span Diagnostic, India).
Biochemical analysis
After 28 days of treatment, blood sample was drawn
from puncture the retro orbital under mild anesthesia
condition, collected blood was centrifuged and examined
for plasma glucose analysis by a GOD - POD method
using the Glucose Estimation Kit (Span Diagnostic,
India). Other serum estimation was done spectrophoto-
metrically using standard kits which include serum



















Coupling constants in Hertz are provided in parenthesis.
Figure 1 Structure of umbelliferone β-D-galactopyranoside.
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(High density lipoprotein) cholesterol (Span Diagnostic,
India) and triglyceride (Span Diagnostic, India). Hexoki-
nase, glucose-6-phosphate and fructose-1-6-biphosphatase
was estimated by the reported method of Brandstrup and
co-researcher [21].
Estimation of antioxidant enzymes
For estimation of antioxidant enzymes, all group rats
liver tissue was homogenized, centrifuged and examined
for superoxide dismutase, catalase, glutathione peroxid-
ase, malonaldehyde levels according to the reported
methods with minor modification [22-25].
Histopathology
At 28 day all the animal sacrificed under mild anesthesia
and different organ (heart, liver, pancreas and kidney) of
the animal was isolated for histopathology studies. The
isolated organ (heart, liver, pancreas and kidney) tissue
fixed with 40% neutral buffered formalin, dehydrated by
passing through a graded series of alcohol, embedded in
paraffin blocks and then 5 mm sections were developed
using a semi-automated rotatory microtome. Hematoxylin
and eosin stain were used.
Statistical data analysis
All the data were expressed as the mean ± S. E. M. an
analysis of variance (ANOVA) was used for the statistical
analysis using Graph Pad Prism version 5.0. The values
were considered to be significant when the P value was
0.001.
Result
Characterization of isolated compound
The methanolic extract of stem of A. marmelos was
subjected to column chromatography. Fractions 40–60
were further purified by silica gel recolumn chromatog-
raphy and the chromatography purified of these frac-
tions led to the isolation of compound (500 mg).
Isolated compound obtained as yellowish coloured solid
compound (3 gm), mp – 240°C, Rf: 0.35, (C7H8/(C2H5)2
O, 1:1), compound exhibited UV absorption bands at
330 nm (log ε 3.1), indicating coumarin derivative. ESI-
MS at m/z (rel. int.): 324 [M]+ C15H16O8 (1.8),
1H NMR
(DMSO-d6): 7.90 (1H, dd, J 9.6, 2.8 Hz, H – 6), 7.51
(1H, d, J = 9.1 Hz, H - 4), 7.20 (1H, d, J = 2.8 Hz, H - 8),
6.91 (1H, d, J = 9.1 Hz, H - 3), 6.91 (1H, d, J = 9.6 Hz,
H - 5), 5.12 (1H, d1, J = 7.2 Hz, H - 1
1), 4.36 (1H, H - 51),
3.82 (1H, H -21), 3.78 (1H, H -31), 3.67 (1H, H -41), 3.16
(2H, H -61). 13C NMR (DMSO-d6): 163.81 ( C-2), 112.06
(C-3), 142.75 (C-4), 128.14 (C-5), 124.32 (C-6), 157.64 (C-
7), 103.25(C-8), 112.16 (C-9), 154.18 (C-10), 105.59 (C-1I),
74.19 (C-2I), 72.21 (C-3I), 68.63 (C-4I), 76.21 (C-5I), 62.05
(C-6I) (Table 1). IR γmax (KBr): 3435, 3390, 2936, 2851,1702, 1607, 1515, 1458, 1425, 1337, 1278, 1224, 1115,
1071 cm-1 (Figure 1) (Additional File 1: Spectral Data of
umbelliferone β-D-galactopyranoside).
Acute toxicity study
An acute toxicity study revealed the non-toxic nature of
the UFG. There was no lethality or any toxic reactions
found at any of the doses selected until the conclusion
of the study period.
Effect of UFG on oral glucose tolerance test
The blood glucose level in rat fed on a normal diet (nor-
mal control, group I) was almost constant throughout
the complete study. The normal control group rat re-
ceived UFG (40 mg/kg) dose significantly showing the
better utilization of glucose (Group II) as compared to
Figure 2 Effect of umbelliferone β-D-galactopyranoside on fasting plasma glucose on oral glucose tolerance test at different concentrations
on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05
is considered as non-significant (ns).
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blood glucose level group rat treated with different doses
of UFG inhibit the high blood glucose level. Three differ-
ent doses of UFG significantly (p < 0.001) inhibit the high
blood glucose level by 13.9%, 17.6% and 29.8% at the
tested doses of 10 mg/kg, 20 mg/kg and 40 mg/kg respect-
ively as shown in Figure 2. Glibenclamide (10 mg/kg) sig-
nificantly (p < 0.001) inhibit glucose excursion by 28%
(Table 2).
Effect of UFG on blood glucose level
The blood glucose level of the rat fed a normal diet (nor-
mal control) remain unchanged at throughout the ex-
perimental study (Group I). In the other group received
normal fed and dose UFG 40 mg/kg (Group II) shown
the blood glucose level near the normal control group rat.
On the contrary, the blood glucose level of STZ induced
diabetic rats was increased significantly (Group III). STZ
diabetic rat treated with different doses of UFG shown sig-
nificantly (P < 0.001) lowering the blood glucose level atTable 2 Effect of umbelliferone β-D-galactopyranoside on blo
normoglycemic rats
S. No. Treatment Dose
Time 0 mi
1 Normal Control - 87.2 ± 0.83
2 Normal Control + UFG 40 mg/kg 86.8 ± 0.73
3 Glucose Control - 88.8 ± 0.86
4 UFG I 10 mg/kg 88.4 ± 0.73
5 UFG II 20 mg/kg 87.4 ± 1.07
6 UFG III 40 mg/kg 88.8 ± 0.73
7 Glibenclamide 10 mg/kg 89 ± 0.707
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non significdose dependent manner shown in Table 3. On the other
hand, glibenclamide (10 mg/kg) significantly inhibit the
blood sugar level (Figure 3).
Effect of UFG of plasma insulin
The levels of plasma insulin in diabetic groups were sig-
nificantly decreased as compared to the normal control
group and UFG dose 40 mg/kg treated normal control
group rat (Table 3). Different doses of UFG (10 mg/kg,
20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg)
received groups significantly (p < 0.001) increase the
level of plasma insulin. The result suggests that the
plasma insulin level of UFG 40 mg/kg maximum in-
crease when compare with the 10 mg/kg, 20 mg/kg and
glibenclamide (Figure 4).
Effect of UFG on total cholesterol
To evaluate the effect of UFG on total cholesterol level,
the diabetic rat received different doses (10 mg/kg,
20 mg/kg and 40 mg/kg) of UFG and glibenclamideod glucose levels in oral glucose tolerance test in
Mean blood glucose concentration ± SEM (mg/dl)
n Time 30 min Time 60 min Time 120 min
7 87.2 ± 0.834 87.8 ± 0.735 87.8 ± 0.583
5 86.4 ± 0.734 84.4 ± 0.245 80.8 ± 0.583
1 140.4 ± 2.315 135 ± 1.143 129 ± 1.963
4 139.4 ± 1.158ns 127.8 ± 1.021* 106 ± 1.145***
7 130 ± 1.158* 116.6 ± 1.435** 101.4 ± 1.032***
4 124.8 ± 1.497** 109 ± 0.732*** 87 ± 1.789***
125 ± 1.068** 111.4 ± 1.034*** 88.6 ± 1.568***
ant; ANOVA, followed by Dunnett’s multiple comparison test.
Table 3 Effect of umbelliferone β-D-galactopyranoside on biochemical parameters in STZ-induced diabetic rats




STZ diabetes + UFG
(10 mg/kg)b
STZ diabetes + UFG
(20 mg/kg)b




1 Fasting plasma glucose (mg/dL) 91.2 ± 1.114 87.6 ± 1.031 394.2 ± 3.992*** 193.2 ± 1.393** 166.2 ± 2.332*** 123.4 ± 2.379*** 136.4 ± 1.99***
2 Fasting Plasma Insulin (μU/mL) 11.2 ± 0.374 12.2 ± 0.374 2.8 ± 0.383*** 4.4 ± 0.509* 6.8 ± 0.374** 9.4 ± 0.519*** 8.6 ± 0.609***
3 Glycated Heamoglobin (A1c) (%) 1.4 ± 0.141 1.36 ± 0.157 4.82 ± 2.49*** 3.8 ± 0.184* 3.42 ± 0.182** 1.86 ± 0.161*** 2.04 ± 0.212***
4 Hexokinase (μg/mg of tissue) 150.4 ± 3.356 152 ± 3.146 100.8 ± 1.655*** 112.6 ± 1.778** 127.6 ± 1.327** 141.2 ± 1.934*** 139 ± 1.225***
5 Glucose-6-Phosphatase
(unit/mg of tissue)
10 ± 0.948 10 ± 1.095 15.4 ± 0.509*** 14.4 ± 0.612ns 12.8 ± 0.374* 10.8 ± 0.583*** 11.6 ± 0.244***
6 Fructose-1-6-biphosphatase
(unit/mg of tissue)
30.8 ± 0.861 29.80 ± 0.489 54.6 ± 2.619*** 47.4 ± 1.166* 38.2 ± 1.281** 32.2 ± 0.861*** 34.8 ± 0.583***
7 Total Cholesterol (mg/dL) 66.6 ± 1.503 64.8 ± 1.655 155.8 ± 3.865*** 97.2 ± 1.158** 82.2 ± 2.417** 61.2 ± 2.131*** 66.2 ± 1.463***
8 Triglycerides (mg/dL) 82.4 ± 3.231 80 ± 1.378 154.6 ± 1.161*** 131.8 ± 1.163* 123.2 ± 1.660** 96.2 ± 1.392*** 108.4 ± 1.071***
9 Total HDL Cholesterol (mg/dL) 58.6 ± 1.913 59.8 ± 4.266 30.8 ± 1.319*** 42.8 ± 1.356* 50.4 ± 0.927** 59.2 ± 1.068*** 55.8 ± 1.167***
10 Total LDL Cholesterol (mg/dL) 37.9 ± 1.206 33.4 ± 1.188 197 ± 6.647*** 118.5 ± 1.201** 65.5 ± 1.391*** 44.4 ± 1.668*** 61.8 ± 1.559***
11 Total VLDL Cholesterol (mg/dL) 16.48 ± 0.326 16 ± 0.276 30.92 ± 0.647*** 26.36 ± 0.232* 24.72 ± 0. 331** 19.24 ± 0.279*** 21.68 ± 0.215***
12 Weight Variation (g) ± 196 ± 0.775 197.6 ± 1.288 165.2 ± 3.382*** 190.4 ± 4.686*** 195 ± 3.761*** 203.2 ± 4.428*** 183.4 ± 5.269***
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non significant; ANOVA, followed by Dunnett’s multiple comparison test.
aCompared to vehicle control.





















































Figure 3 Effect of umbelliferone β-D-galactopyranoside on fasting plasma glucose at different concentrations on STZ induced diabetic
rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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rat as compared to the normal control group and UFG
dose 40 mg/kg treated normal control group rat (Table 3).
Different doses of UFG (10 mg/kg, 20 mg/kg and
40 mg/kg) and glibenclamide (10 mg/kg) received group
decreasing the level of total cholesterol as compared to
the diabetic control groups rat. UFG dose 40 mg/kg is
more effective to decrease the level of total cholesterol as
compared to other group treated with different doses of
UFG (10 mg/kg, 20 mg/kg) and glibenclamide (Figure 5).Effect of UFG on triglyceride
The level of triglyceride is increased in STZ induced dia-
betic rat as compared to the normal control group and
UFG dose 40 mg/kg treated normal control group rat
(Table 3). Increase the level of triglyceride in STZ in-
duced diabetic group, treated with different doses of UFG
(10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide
(10 mg/kg) significantly inhibit the level of triglyceride.
UFG 40 mg/kg is most effective in dose on inhibiting the
maximum level of triglyceride as compared to 10 mg/kg,





















Figure 4 Effect of umbelliferone β-D-galactopyranoside on level of pl
rats, compared to diabetic control group rats; values are mean ± SEM
non-significant (ns).Effect of UFG on total HDL (high density lipoprotein)
cholesterol
To evaluate the effect of UFG on total HDL cholesterol,
the level of HDL cholesterol was decreased in STZ
treated diabetic rat as compared to the normal control
group and UFG dose 40 mg/kg treated normal control
group rat (Table 3). The effect of different doses of UFG
(10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide
(10 mg/kg) significantly increases the level of HDL chol-
esterol. UFG 40 mg/kg doses shown the maximum in-
creasing the level of HDL cholesterol as compared to
10 mg/kg, 20 mg/kg doses of UFG and glibenclamide
(10 mg/kg) treated group (Figure 7).Effect of UFG on total LDL (low density lipoprotein)
cholesterol
In STZ induced diabetic rat increased the level of LDL
cholesterol as compared to the normal control group
and UFG dose 40 mg/kg treated normal control group rat.
The effect of different doses of UFG and glibenclamide in
STZ induced diabetic rat significantly (P < 0.001) inhibit
the increased level of LDL cholesterol (Table 3). Theasma insulin at different concentrations on STZ induced diabetic
























Figure 5 Effect of umbelliferone β-D-galactopyranoside on level of total cholesterol at different concentrations on STZ induced diabetic
rats, compared to diabetic control group rats; values are mean± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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appeared in the group received UFG 40 mg/kg (Figure 8).
Effect of UFG on total VLDL (very low density lipoprotein)
cholesterol
To evaluate the effect of UFG on VLDL (very low dens-
ity lipoprotein) cholesterol, in STZ induced diabetic rat
increased the level of VLDL cholesterol as compared to
the normal control group and UFG dose 40 mg/kg
treated normal control group rat. Diabetic rat treated
with different doses of UFG and glibenclamide signifi-
cantly (P < 0.001) decreasing the level of VLDL choles-
terol. Diabetic rats treated with UFG 40 mg/kg showed
the maximum augmentation in the level of VLDL chol-
esterol as compared to other groups received different
doses of UFG and glibenclamide (Figure 9).
Effect of UFG on hexokinase
The level of hexokinase decrease in STZ treated group
as compared to the normal control group and UFG dose
40 mg/kg treated normal control group rat (Table 3).
Diabetic groups rat treated with different doses of UFG
(10 mg/kg, 20 mg/kg and 40 mg/kg) and glibenclamide





















Figure 6 Effect of umbelliferone β-D-galactopyranoside on level of tr
rats, compared to diabetic control group rats; values are mean ± SEM
non-significant (ns).Diabetic rat treated with dose 40 mg/kg UFG show max-
imum growth in the level of hexokinase as compared to
other groups received 10 mg/kg, 20 mg/kg dose of UFG
and glibenclamide (Figure 10).
Effect of UFG on glucose-6-phosphate
To evaluate the effect of different doses of UFG on
glucose-6-phosphate on diabetic rat (Table 3). The level
of glucose-6-phosphate was significantly increased in
diabetic groups rat when compared to the normal
control group and UFG dose 40 mg/kg treated normal
control group rat. Diabetic rat treated with different
doses of UFG (10 mg/kg, 20 mg/kg and 40 mg/kg) and
glibenclamide (10 mg/kg) significantly decrease the level
of glucose-6-phosphate. UFG 40 mg/kg dose shown a
maximum increase in the level of glucose-6-phosphate
when compared to 10 mg/kg, 20 mg/kg dose of UFG
and glibenclamide (10 mg/kg) dose received groups
(Figure 11).
Effect of UFG on fructose-1-6-biphosphatase
The oral administration of different doses of UFG decreases
the level of fructose-1-6-biphosphatase as compared to the
normal control group and UFG dose 40 mg/kg treateda
iglyceride at different concentrations on STZ induced diabetic

























Figure 7 Effect of umbelliferone β-D-galactopyranoside on level of HDL (High density lipoprotein) cholesterol at different concentrations
on STZ induced diabetic rats, compared to diabetic control group rats; values are mean± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001;
P > 0.05 is considered as non-significant (ns).
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biphosphatase increase in STZ induced diabetes (Table 3).
Diabetic groups received different doses of UFG (10 mg/kg,
20 mg/kg and 40 mg/kg) and glibenclamide (10 mg/kg) de-
crease the level of fructose-1-6-biphosphatase. The UFG
dose 40 mg/kg shown the supreme diminish levels of
fructose-1-6-biphosphatase comparison to other diabetic
treated group received dose 10 mg/kg, 20 mg/kg dose of
UFG and glibenclamide (Figure 12).Effect of UFG on glycated hemoglobin (A1c)
The level of glycated hemoglobin (A1c) increased in
STZ-induced treated diabetic rats as compared to the
normal control group and UFG dose 40 mg/kg treated
normal control group rat (Table 3). The treated group
with different doses of UFG (10 mg/kg, 20 mg/kg and
40 mg/kg) and glibenclamide (10 mg/kg) significantly in-
hibit the level of glycated hemoglobin (A1c). UFG dose
40 mg/kg treated group significantly inhibits the level of
glycated hemoglobin (A1c) as compared to 10 mg/kg,

























Figure 8 Effect of umbelliferone β-D-galactopyranoside on level of LDL
on STZ induced diabetic rats, compared to diabetic control group rats;
P > 0.05 is considered as non-significant (ns).Effect of UFG on malondialdehyde (MDA)
The level of MDA in untreated diabetic control rats was
significantly higher than those in the normal control
group and UFG dose 40 mg/kg treated normal control
group rat (Table 4). Different doses of UFG (10 mg/kg,
20 mg/kg and 40 mg/kg) administered groups signifi-
cantly (p < 0.001) inhibit the level of MDA. The max-
imum inhibition at the level of MDA seen in the group
treated with 40 mg/kg of UFG. On the other hand
standard drug (glibenclamide) also inhibits the increas-
ing level of MDA in diabetic rats. The outcome suggests
that UFG dose 40 mg/kg is more effective than the other
doses of UFG and glibenclamide (Figure 14).Effect of UFG on glutathione peroxidase (GPx)
The level of GPx was significantly (p < 0.001) decreased
in diabetic control groups as compared to the normal
control group and UFG dose 40 mg/kg treated normal
control group rat (Table 4). Glibenclamide (10 mg/kg)
and different doses of UFG (10 mg/kg, 20 mg/kg and
40 mg/kg) received groups significantly (p < 0.001) in-
crease the level of GPx. The outcome suggests thata
(Low density lipoprotein) cholesterol at different concentrations

























Figure 9 Effect of umbelliferone β-D-galactopyranoside on level of VLDL (very low density lipoprotein) cholesterol at different concentrations
on STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is
considered as non-significant (ns).
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the level of GPx as compared with other group rats
received different doses of UFG and glibenclamide
(Figure 15).
Effect of UFG on superoxide dismutase (SOD)
The level of antioxidant enzyme SOD was significantly
decreased in diabetic control groups as compared to the
normal control group and UFG dose 40 mg/kg treated
normal control group rat (Table 4). Glibenclamide
(10 mg/kg) and different doses of UFG (10 mg/kg,
20 mg/kg and 40 mg/kg) received groups significantly
(p < 0.001) increase the level of SOD. The outcome sug-
gests that glibenclamide and all the doses of UFG in-
crease the level of SOD, but UFG doses 40 mg/kg was
more effective in increase the level of SOD in diabetic
rat as compared with different doses of UFG and
glibenclamide (Figure 16).
Effect of UFG on catalase (CAT)
The level of CAT were significantly (p < 0.001) decreased
in diabetic control groups when compared to the normal
control group and UFG dose 40 mg/kg treated normal




























Figure 10 Effect of umbelliferone β-D-galactopyranoside on level of H
rats, compared to diabetic control group rats; values are mean ± SEM
non-significant (ns).and different doses of UFG (10 mg/kg, 20 mg/kg and
40 mg/kg) received groups rat significantly (p < 0.001)
increase the level of CAT. The data suggest that UFG
40 mg/kg dose was more effective to increase the level of
CAT in diabetic rats as compared with other groups rat
received different doses and glibenclamide (Figure 17).
Changes in body weight
At the end of 28 days treatment, the body weight of
normal rats, UFG dose 40 mg/kg treated normal
rat, diabetic control, different doses of UFG and
glibenclamide treated rats observed (Table 3). Diabetic
control group continued to lessen the weight till the
conclusion of the study. Glibenclamide and UFG differ-
ent doses (10 mg/kg, 20 mg/kg and 40 mg/kg) treated
rats significantly increased the weight as compared to
the diabetic control rats (Figure 18).
Effect of UFG on liver
Histopathology studies of STZ induced diabetic rat
shown the accumulation of fat and large area of hepato-
cytes taken over by macro droplet of fat in the liver. Oral
administration of different doses of UFG improved the
histopathology conditions. UFG dose 10 mg/kg dosea
exokinase at different concentrations on STZ induced diabetic






































Figure 11 Effect of umbelliferone β-D-galactopyranoside on level of Glucose-6-phosphatase at different concentrations on STZ
induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is
considered as non-significant (ns).
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UFG 20 mg/kg dose shown some micro droplet of fat
accumulation on rat histopathology. Dose UFG 40 mg/kg
shown the rat liver histopathology similar to the gli-
benclamide drugs (Figures 19 and 20).
Effect of UFG on kidney
Study of STZ induced diabetes rat kidney histopathology
shown inflammation in blood vessels, fat deposition, in-
crease in the thickness of bowman capsules and change in
size of the glomerulus. Treatment with different doses of
UFG improves the injured rat kidney with increasing doses.
The treatment with UFG 10 mg/kg dose showed improved
kidney histopathology less inflammatory blood vessels, less
fat deposition as compared to diabetic control. Treatment
with UFG 20 mg/kg dose shown only fat deposition no in-
flamed blood vessels and the dose UFG 40 mg/kg shown
the normal histopathology there is no inflammatory vessels
and no fat deposition (Figures 21 and 22).
Effect of UFG on pancreas
Histopathology studies of pancreas of STZ induced dia-








































Figure 12 Effect of umbelliferone β-D-galactopyranoside on level of F
induced diabetic rats, compared to diabetic control group rats; value
considered as non-significant (ns).damaged or reduced the size of β cells and extensive ne-
crosis changes followed by fibrosis and atrophy. STZ in-
duced diabetic rat treated with different doses of UFG
and glibenclamide restored the necrotic and fibrotic
changes and raised the number of β cells (Figures 23
and 24).
Effect of UFG on heart
Heart histopathology study of STZ induced diabetic rat
shown increased the interstitial space, intercalated disc
and level of fat deposition. Oral administration of UFG
decreased the interstitial, intercalated disc and fat depos-
ition at dose dependent manner. UFG dose 40 mg/kg
was more effective to show normal histopathology of
heart (Figures 25 and 26).
Discussion
The isolated compound was identified as umbelliferone β-
D-galactopyranoside using different spectroscopy FT-IR,
ESI-MS, 1H-NMR, 13C-NMR. IR absorption spectrum at
1702 cm-1 and the compound exhibit blue fluorescence
and UV absorption maxima at 256, 277 and 330 NM for
δ-lactone ring suggested coumarin nature of the isolatedructose1-6-biphosphate at different concentrations on STZ





























Figure 13 Effect of umbelliferone β-D-galactopyranoside on level of glycated hemoglobin (A1c)(%) at different concentrations on STZ
induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is
considered as non-significant (ns).
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ESI-MS at m/z (rel. int.): 324 [M]+ consistent with the
molecular formula of C15H16O8. It also had IR absorption
bands for hydroxyl groups (3435, 3390, 2936 cm-1), and
an aromatic ring (1607, 1515 cm-1). The 1H NMR
spectrum showed the presence of two AB-type double at
δ 6.91 (J = 9. 1 Hz) and 7.51 (J = 9. 6 Hz) assigned to vi-
nylic H-3 and H-4 protons, respectively. One-proton
double douplet at δ 7.90 (J = 7.2, 2.8 Hz) and two on –pro-
ton doublets at δ 7.20 (J = 2.8 Hz) and 6.91 Hz (J = 9.1)
was ascribed to coumarin H-6, H-8 and H-5 protons, re-
spectively. One-proton doublets at δ 5.12 (J = 7.2 Hz) were
accounted to α-oriented anomeric H-1I protons, respect-
ively. The other sugar protons resonated between δ 4.36 –
3.16. The 13C NMR spectrum displayed signals for nine
coumarin carbons in the range of δ 163.81 – 103.25,
anomeric carbon at δ 105.59 (C-1I) and other sugar car-
bons between δ 74.19 – 62.05. The existence of an NMR
H-2I signal in the deshielded region at δ 3.82 and carbon
C-2I signal at δ 74.19 indicated (2I→ 1II) linkage of the
sugar units. The HMBC spectrum of the coumarin
showed interactions of H-6, H-8 and H-1I with C-7; H-3












212.4 ± 2.839 213 ± 2.608 73.8 ± 4.005***
2 CAT (U/mg
of protein)
135.8 ± 3.652 136.6 ± 3.894 60.8 ± 1.562***
3 GPx (nmole/mg
of protein)
33.2 ± 2.267 34.2 ± 2.267 14 ± 0.836***
4 MDA (nmole/mg
of protein)
0.241 ± 0.007 0.222 ± 0.009 0.522 ± 0.016***
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non signific
a Compared to vehicle control.
b Compared to diabetic control.spectral data of the coumarin nucleus were compared
with the reported data of other coumarins [26-28]. On the
basis of spectral data analysis the structure of this new
compound has been elucidated as Umbelliferone β-D-
galactopyranoside. More than 100 compounds already
isolated from the Aegle marmelos Correa but umbelliferone
β-D-galactopyranoside isolated first time in this plant.
Different part of the plant Aegle marmelos having the very
long history to cure the diabetes but the lack of single bio-
active compound was still unknown. In this manuscript we
have isolated the bioactive compound UFG (umbelliferone
β-D-galactopyranoside) from the bark and look into the
antidiabetic activity in normal and diabetic rat models. The
result showed that the different doses of UFG significantly
decrease the blood sugar level, total cholesterol, total trigly-
ceride, total HDL, LDL cholesterol of diabetes rats and
demonstrated the antioxidant activity (SOD, CAT, GPx,
MDA) as compared to diabetic control group and gliben-
clamide group rats.
STZ is a nitrosourea compound, widely used cytotoxic
agent and obtained from the soil microbe Streptomyces
achromogenes, which effect on pancreatic β-cells induced








149.4 ± 5.391** 175.2 ± 3.353** 198.2 ± 3.247*** 202.6 ± 3.776***
85 ± 3.286* 97.8 ± 2.939** 130.2 ± 3.397*** 129.2 ± 2.154***
21 ± 0.707** 24.6 ± 0.872** 31.2 ± 1.068*** 28.8 ± 0.811***
0.396 ± 0.017* 0.312 ± 0.008** 0.274 ± 0.011*** 0.261 ± 0.014***



























Figure 14 Effect of umbelliferone β-D-galactopyranoside on level of MDA (Malondialdehyde) cholesterol at different concentrations on
STZ induced diabetic rats, compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001;
P > 0.05 is considered as non-significant (ns).
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of insulin; as a result the level of insulin increase in
blood, due to increasing levels of insulin it increases the
level of blood glucose [30].
The Wister rats treated with different doses of UFG
orally exhibited normal behaviour till doses 100 mg/kg,
these groups behave normally on touching and pain re-
sponse. There was no lethality or any toxic reactions
found with the selected dose until the conclusion of the
field. The dose of the test drug has been selected on the
basis of dose calibration curve methods.
Different category of synthetic oral hypoglycemic agents
currently available in the treatment and control of NIDDM
(non insulin dependent diabetes mellitus) including
thiazolidinediones, sulphonylureas, biguanides, α – gluco-
sidase inhibitors. Glibenclamide (used as the reference
hypoglycemic agent in this study) [31]. Glibenclamide is a
sulphonylurea class of drug and the most probable mech-
anism of action is inducing insulin secretion.
OGTT in the wistar rat model showed that different
doses of UFG significantly reduced the glucose excursion
in a dose dependent manner. Normal control group un-
changed at the end of the study but normal control



























Figure 15 Effect of umbelliferone β-D-galactopyranoside on level of GP
on STZ induced diabetic rats, compared to diabetic control group rats;
P > 0.05 is considered as non-significant (ns).better utilization of glucose as compared to the normal
control. Different doses of UFG exhibited remarkable
decreasing the blood sugar lowering effect in the glucose
tolerance test. UFG dose 40 mg/kg is more effective than
the glibenclamide (Figure 2).
The outcome suggests that diabetic control group se-
verely causing hyperglycaemia as compared to the nor-
mal control group. Comparing with the different doses
of UFG treated group rats significantly lowered the ele-
vated blood glucose level (Figure 3). During this investi-
gation elevation of fasting plasma glucose level in
diabetic control group rats at the end of the 28 day ex-
perimental period significantly (P < 0.001) observed. Dif-
ferent doses of UFG and glibenclamide treated diabetic
rats showed significant (P < 0.001) reduction of initial
fasting plasma glucose level and increasing the serum in-
sulin level (Figure 4). Thus, the possible mechanism of
action of UFG is potentiating the insulin by increasing
either the pancreatic secretion of insulin from the
existing cells or by releasing the bound form. Type I and
Type II diabetes patient suffered from atherosclerosis
(Coronary artery disease) which may cause the death [32].
Not only the atherosclerosis and other factor like hypertri-
glyceridemia, hypercholesterolemia and hypertension mayx (Glutathione peroxidase) cholesterol at different concentrations

























Figure 16 Effect of umbelliferone β-D-galactopyranoside on level of SOD (Superoxide dismutase) cholesterol at different concentrations
on STZ induced diabetic rats, compared to diabetic control group rats; values are mean± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001;
P > 0.05 is considered as non-significant (ns).
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abnormality is circulating diabetes and glucose intolerance
(having tendency to develop the diabetes) patient by in-
sensitivity of peripheral tissue of insulin [36]. In STZ in-
duced diabetic rat significant (P < 0.001) increase level of
total cholesterol, total triglyceride, total VLDL cholesterol
and decrease levels of HDL cholesterol was observed. The
outcome of the experiment reveals that continue doses of
UFG administered to animals for 28 days nearly normal-
ized the lipid profile in diabetic induced group rats. Differ-
ent doses of UFG treated diabetic rats, shows marked
reduction in total cholesterol (Figure 5), total triglyceride
(Figure 6), total HDL cholesterol ((Figure 7), LDL choles-
terol (Figure 8) and elevate the level of VLDL cholesterol
(Figure 9) showed the hypolipidemic effect of UFG. The
most effective doses of UFG 40 mg/kg not only decreases
the level of TC, TG, and LDL but also improved the
cardioprotective lipid HDL. In normal metabolism insu-
lin activates the enzyme lipoprotein lipase enzyme and
triglyceride hydrolysis. In diabetic condition deficiency
of insulin inactivated the both enzyme and causes the
hypertriglyceridemia [37].
Another mechanism of action of UFG may be increasing





















Figure 17 Effect of umbelliferone β-D-galactopyranoside on level of C
induced diabetic rats, compared to diabetic control group rats; value
considered as non-significant (ns).in postprandial hyperglycemia and the synthesis of
glycogen. Hexokinase, glucose-6-phosphate and fructose-
1-6-biphosphatase are the enzyme found in the liver and
they convert glucose into energy, utilize the glucose, syn-
thesis of glycogen etc. In the liver, hexokinase convert glu-
cose into glucose-6-phosphatase [38,39]. In STZ induced
diabetic rats inhibit the synthesis of glycogen and inhibit
the level of hexokinase. Decreasing the level of hexokinase
inhibits the conversion of glucose into glucose-6-
phosphate and increasing the level of glucose in the blood
[40]. The STZ induced diabetic rats treated with different
doses of UFG and glibenclamide has increased the level of
hexokinase and increase the utilization of glucose to en-
ergy conversion (Figure 10). In an earlier discussion it
shows that glucose-6-phosphate regulates the glucose me-
tabolism with the help of hexokinase. In STZ induced rats
increased the level of glucose-6-phosphate, increasing
levels of glucose-6-phosphate improves the activity of a
gluconeogenetic enzyme and enhance the manufacturing
of fats from carbohydrates, due to excess manufacturing
of fats, it starts deposition on kidney and liver [41,42].
STZ induced diabetic rats treated with different doses of
UFG and glibenclamide had normalized the activity of
glucose-6-phosphatase enzyme near to normal control bya
AT (Catalase) cholesterol at different concentrations on STZ






















Figure 18 Effect of umbelliferone β-D-galactopyranoside on body weight at different concentrations on STZ induced diabetic rats,
compared to diabetic control group rats; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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Another vital liver enzyme fructose-1-6-biphosphate play
an important role in the glycolysis (conversion of glucose
into energy) [43,44]. STZ induced diabetic group rat
showed the increase level of fructose-1-6-biphosphate.
Due to increase level of the fructose-1-6-biphosphate de-
cline the glycolysis and stop the conversion of glucose into
energy. STZ induced diabetic groups treated with different
doses of UFG and glibenclamide decreasing the elevatedFigure 19 Umbelliferone β-D-galactopyranoside (UFG) effect on
liver in different groups of rats: (A) Normal control: Normal
control group did not produce any changes in histopathology
(B) Diabetic control: Diabetic control group rat shown enlarged
of micro droplet of fat (yellow arrow) (C) UFG I (10 mg/kg):
Treatment with UFG dose (10 mg/kg) shown some part having
micro droplet of fat deposition (yellow arrow). (D) UFG II
(20 mg/kg): Treatment with different dose UFG (20 mg/kg) shown
few particle of micro droplet of fat in liver histopathology (yellow
arrow). (E) UFG III (40 mg/kg): Histopathology of UFG (40 mg/kg)
drug not showing any fat deposition and other assortments.
(F) Glibenclamide (10 mg/kg): Standard drug treated group shown
histopathology similar to the normal control groups. The samples
were obtained from the same liver anatomical regions. For each
group, 6 rats were examined and 80 pictures were taken. The above
picture for each group was chosen randomly from the 80 pictures in
this group. Original magnification, 10 × .level of fructose-1-6-biphosphate and brought back to
normal level (Figure 12).
STZ induced diabetic rats showed increase the level of
glucose in the blood which adds to the RBC (red blood
cells) in the N terminal of hemoglobin chain and starts
the production of glycated hemoglobin. The level of
glycated hemoglobin was increased up to 16% in dia-
betes mellitus [45]. Sometime glycated hemoglobin can
be used as an indicator of metabolic control of diabetesFigure 20 Effect of umbelliferone β-D-galactopyranoside (UFG)
on liver in different groups of rat: (A) Normal control: Normal
control group Shown normal histopathology (B) Diabetic
control: In histopathology of diabetic control group rat shown
overblown of micro droplet of fat (yellow arrow indicate) (C)
UFG I (10 mg/kg): Histopathology of UFG dose (10 mg/kg)
shown deposition of some micro droplet of fat (yellow arrow).
(D) UFG II (20 mg/kg): In the histopathology of dose UFG (20 mg/
kg) showed few micro droplet deposition of fat (yellow arrow).
(E) UFG III (40 mg/kg): Histopathology of UFG (40 mg/kg) drug not
showing any fat deposition and other changes. (F) Glibenclamide
(10 mg/kg): Histopathology of glibenclamide treated drug group
shown similar to the normal control groups. The samples were
obtained from the same liver anatomical regions. For each group, 6
rats were examined and 80 pictures were taken. The above picture
for each group was chosen randomly from the 80 pictures in this
group. Original magnification, 40 × .
Figure 21 Effect of umbelliferone β-D-galactopyranoside (UFG)
on histopathology study of kidney in different groups of rat: (A)
Normal control: Normal control group rat histopathology shown
normal size of glomerulus (B) Diabetic control: Diabetic control
rat histopathology shown inflammatory cell in blood vessels
(blue arrow) and deposition of fats (yellow arrow) (C) UFG I
(10 mg/kg): Tested drug UFG (10 mg/kg) treated group rat
histopathology shown inflammation in blood vessels (brown
arrow) and fat deposition (yellow arrow) (D) UFG II (20 mg/kg):
Dose UFG (20 mg/kg) treated group rat histopathology shown
only fat deposition (yellow arrow) no inflammatory blood cells.
(E) UFG III (40 mg/kg): Treatment with dose UFG (40 mg/kg) group rat
histopathology shown kidney histopathology like the glibenclamide
treated group (F) Glibenclamide (10 mg/kg): Histopathology of
Glibenclamide treated group rat shown the normal kidney. The
samples were obtained from the same liver anatomical regions. For
each group, 6 rats were examined and 80 pictures were taken. The
above picture for each group was chosen randomly from the 80
pictures in this group. Original magnification, 10 × .
Figure 22 Effect of umbelliferone β-D-galactopyranoside (UFG)
on histopathology of kidney normal and STZ treated groups rat:
(A) Normal control: Average size of glomerulus shown in the
normal group rat histopathology. (B) Diabetic control: Inflammatory
cells in blood vessels (blue arrow) and fat deposition (yellow arrow)
shown in the histopathology of diabetic control group rat. (C) UFG I
(10 mg/kg): Some inflammatory cell in blood vessels (blue arrow) and
deposition of fat (yellow arrow) found in the histopathology of UFG I
(10 mg/kg) treated groups’ rat. (D) UFG II (20 mg/kg): Only fat
deposition (yellow arrow) shown in the histopathology of UFG II
(20 mg/kg) treated group rat. (E) UFG III (40 mg/kg): Histopathology of
dose UFG (40 mg/kg) treated group rat shown average size of
glomerulrs but slightly bigger in size as compared to the normal
control. (F) Glibenclamide (10 mg/kg): Histopathology of glibenclamide
treated group animal shown the histopathology similar to the normal
kidney. The samples were obtained from the same liver anatomical
regions. For each group, 6 rats were examined and 80 pictures were
taken. The above picture for each group was chosen randomly from
the 80 pictures in this group. Original magnification, 40 × .
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diabetes in metabolic control. In normal condition
glycated hemoglobin makes up 3.4-5.8% of total hemo-
globin and small volume of blood glucose. Only 4.5-6% of
glycated hemoglobin covalently bonded to the RBC in
hemoglobin [46]. In our research exertion the level of
glycated hemoglobin was elevated more than 4 times
higher in the normal control rats. STZ diabetic rats
treated with different doses of UFG significantly lowering
the higher level of glycated hemoglobin (Figure 13), which
indicate the improved level of glycemic control.
Several method are involved in reactive oxygen species
in diabetes, such as production of lipid peroxidation
(LPO) and glucose autooxidation, protein glycation, for-
mation of advanced glycation products and polyol path-
way [47]. STZ induced diabetes destroy the pancreatic
insulin secreting β-cells and cause enhancing the level of
reactive oxygen species (ROS), increase level of ROS
damaging the tissue in the body. In the production of
ROS oxygen free radical (polyunsaturated fatty acids)
play as significant role [48,49], ROS react with all bio-
logical substances and cell membrane constituent, lead
to increasing the level of lipid peroxidation. Increased
level of LPO impairs membrane function by inhibiting
the membrane fluidity and altering the activity ofmembrane bound enzymes and receptors [48]. The role
of natural and synthetic antioxidant is alteration of this
damage. The MDA (an indicator of LPO) increased the
level in diabetic rat (Figure 14). STZ induced diabetic rat
groups treated with different doses of UFG significantly
decreased the level of MDA. Increase level of GPx
(Glutathione Peroxidase) which lead to deactivation of
LPO reactions (Figure 15). Another primary enzyme
such as SOD is capable of changing the superoxide rad-
ical to hydrogen peroxide and CAT (catalase) is able to
inhibit hydrogen peroxide and involved in detoxification
of hydrogen peroxide concentrations. In our investiga-
tion the SOD, CAT and GPx level were significantly de-
creased and level of MDA was increased in the different
doses of UFG treated groups (Figures 16 and 17) [50].
The reduction in the body weight of diabetic rats was
observed in the throughout study of diabetes. The
weight was reduced due to gluconeogenesis (catabolism
of proteins and fats). Diabetic condition increases the
muscle destruction or degradation of structural proteins
in catabolism of fats and protein [51]. Different doses
and glibenclamide treated STZ induced diabetes groups
rat increases the body weight and also demonstrates the
protective effect against the controlling the muscle wast-
ing (Figure 18).
Figure 25 Effect of Umbelliferone β-D-galactopyranoside (UFG)
photomicrographs of histological change on heart in different
groups of rats: (A) Normal control: Normal control group rat
showing normal histopathology. (B) Diabetic control: Increased
interstitial space and distort the intercalated disc (yellow arrow) in
diabetic control group rat histopathology. (C) UFG I (10 mg/kg): Dose
UFG (10 mg/kg) treated group rat showing less interstitial space and
intercalated disc (yellow arrow) (D) UFG II (20 mg/kg): Dose UFG
(20 mg/kg) treated group rat showing only space in intercalated disc
(yellow arrow). (E) UFG III (40 mg/kg): Dose UFG (40 mg/kg) treated
group rat did not showing any changes in histopathology of heart. (F)
Glibenclamide (10 mg/kg): Glibenclamide (5 mg/kg) treated drug
shown the normal histopathology of heart. The samples were obtained
from the same liver anatomical regions. For each group, 6 rats were
examined and 80 pictures were taken. The above picture for each
group was chosen randomly from the 80 pictures in this group.
Original magnification, 10 × .
Figure 24 Effect of Umbelliferone β-D-galactopyranoside (UFG)
photomicrographs of histological changes in rat pancreas: (A)
Normal control: normal histological structure of rat pancreas
showing normal islet (white arrow) (B) Diabetic control:
Histopathology of diabetic control rat showing focal necrosis
(yellow arrow) (C) UFG I (10 mg/kg): Histopathology of tested
drug rat showing bigger size of islet and focal necrosis (yellow
arrow) (D) UFG II (20 mg/kg): Histopathology of tested drug rat
showing focal necrosis (yellow arrow) (E) UFG III (40 mg/kg):
Histopathology of tested drug rat showing normal size of islet
(white arrow) (F) Glibenclamide (10 mg/kg): glibenclamide
treated rat pancreas showing normal islet (white arrow). For each
group 6 rats were examined and 80 pictures were taken. The above
picture for each group was chosen randomly from the 80 pictures in
this group. Original magnification, 40 × .
Figure 26 Effect of Umbelliferone β-D-galactopyranoside (UFG)
photomicrographs of histological on heart in different groups of
rats: (A) Normal control: Histopathology of normal control group
rat normal histopathology of heart (B) Diabetic control:
Histopathology of diabetic control group rat shown increased
interstitial space and distort the intercalated disc (yellow arrow)
(C) UFG I (10 mg/kg): Histopathology of tested drug shown
decreased interstitial space and intercalated disc (yellow arrow)
(D) UFG II (20 mg/kg): Histopathology of tested drug shown less
interstitial space (yellow arrow) (E) UFG III (40 mg/kg):
Histopathology of tested drug shown normal heart like the
glibenclamide (F) Glibenclamide (10 mg/kg): Histopathology of
glibenclamide treated drug shown the normal histopathology of
heart. The samples were obtained from the same liver anatomical
regions. For each group, 6 rats were examined and 80 pictures were
taken. The above picture for each group was chosen randomly from
the 80 pictures in this group. Original magnification, 40 × .
Figure 23 Effect of umbelliferone β-D-galactopyranoside (UFG)
photomicrographs of histological changes in rat pancreas: (A)
Normal control: Histological structure of normal control group rat
pancreas showing the normal islet (white arrow) (B) Diabetic
control: Focal necrosis (yellow arrow) showed in the
histopathology of diabetic control group rat. (C) UFG I (10 mg/kg):
Treatment Histopathology of tested drug rat showing bigger size of
islet and focal necrosis (yellow arrow) (D) UFG II (20 mg/kg):
Histopathology of tested drug rat showing focal necrosis (yellow
arrow) (E) UFG III (40 mg/kg): Histopathology of tested drug rat
showing normal size of islet (white arrow) (F) Glibenclamide
(10 mg/kg): glibenclamide treated rat pancreas showing normal islet
(white arrow). For each group 6 rats were examined and 80 pictures
were taken. The above picture for each group was chosen randomly
from the 80 pictures in this group. Original magnification, 10 × .
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rat well supported the antidiabetic effect showing a con-
siderable regeneration in the β cells of the pancreas with
treated with umbelliferone β-D-galactopyranoside at
40 mg/kg; p.o. the antidiabetic effect of umbelliferone β-
D-galactopyranoside may be attributed to the positive
influence on endocrine cells of the pancreas resulting in
increased production of insulin.
Histopathology studies performed on the STZ induced
diabetic rat kidney showed damage to the glomerulus,
enhancement in the mucopolysaccharide deposition,
thickened basement membrane and edematous proximal
convoluted tubules were found. Oral treatment of UFG
shown absent of the damage glomerulus, edematous
proximal convoluted with increased in mucopolysac-
charide deposition at dose dependent manner. The study
was performed in shorter duration and this might be in-
sufficient for significant vascular changes in the kidney
of the diabetic rats. Different doses of UFG treated dia-
betic rat however showed healing features, which resem-
bled that of a normal kidney.Conclusions
In conclusion, the present investigation indicates that
umbelliferone β-D-galactopyranoside has significant anti-
diabetic, antihyperlipidemic and antioxidant activity in
STZ induced diabetic rat. Therefore, umbelliferone β-D-
galactopyranoside may be regarded as one of the major at-
tributes for the antidiabetic potential of Aegle marmelos
Correa. Thus, umbelliferone β-D-galactopyranoside can
serve as a lead molecule for further development of drugs
that can possess significantly antidiabetic, antihyper-
lipidemic and antioxidant activity. However, auxiliary in-
vestigations are required to experience the fully elucidate
mechanism and clinical implications by which umbel-
liferone β-D-galactopyranoside decreases elevated blood
glucose in diabetic rats.Additional file
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